Enhanced Genomics key facts
as of Oct 2026- Developer of a biotechnology platform designed to develop tools for large-scale analysis of genetic variations and gene function.
- Enhanced Genomics is valued at approximately $28.1M as of Oct 2026 (last reported valuation).
- It has raised $21.8M; the latest was Later Stage VC ($19.0M) in Sep 2025.
- Notable investors include BGF (Financial Services), Parkwalk Advisors, Meltwind Advisory, Jonathan Milner, Vincent Tchenguiz — 9 tracked in total.
- Status: Privately Held (backing).
Enhanced Genomics's last reported valuation, Sep 2025. Nothing priced has surfaced since.
- ·Watch Enhanced Genomics: the Monday email on marks, rounds and moves
Enhanced Genomics funding rounds
No funding rounds for Enhanced Genomics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Enhanced Genomics valuation
Enhanced Genomics's last reported valuation was $28.1 million in Sep 2025. No priced round, secondary trade or fund mark has surfaced since.
Enhanced Genomics investors
9 investors are on record for Enhanced Genomics, including BGF (Financial Services), Parkwalk Advisors, Meltwind Advisory and Jonathan Milner.
About Enhanced Genomics
Developer of a biotechnology platform designed to develop tools for large-scale analysis of genetic variations and gene function. The company's technology specializes in profiles of three-dimensional genome folding at high resolution for all genes and their enhancers simultaneously, enabling researchers to focus on the advancement of novel drugs in areas of unmet medical needs.
- Sector
- Healthcare
- HQ
- Cambridge, United Kingdom
- Founded
- 2020
- Employees
- 24
- Website
- enhancedgenomics.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.